Can donor plasma fix clotting issues in sepsis? new study investigates

NCT ID NCT04580563

Completed Disease control Sponsor: University Hospital, Strasbourg, France Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tests whether a special donor plasma product called OctaplasLG can help people with septic shock who develop blood clotting problems. Sixty participants will receive either OctaplasLG or a placebo (salt water) to see if the treatment improves clotting and outcomes. The goal is to see if this approach is feasible and worth studying further.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: OctaplasLG (a standardized donor plasma product)
What this could lead to: If it works, this could point toward a treatment to correct dangerous clotting problems in septic shock patients.
What could go wrong: This is a small feasibility study with only 60 participants, so results may not be conclusive. The treatment may not improve survival or could cause side effects like allergic reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COAGULOPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

blood coagulation disease disseminated intravascular coagulation toxic shock syndrome vascular hemostatic disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COAGULOPATHY DISSEMINATED INTRAVASCULAR COAGULATION SEPTIC SHOCK

Contacts and locations

Locations

Hôpitaux Universitaires de Strasbourg

Strasbourg, 67000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.